Prestige Consumer Healthcare Inc.

PBH

US74112D1019

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 15:39:22 2024-07-05 EDT			5-day change	1st Jan Change
67.97 ^USD	+0.97%		-1.44%	+10.85%

06-21	DA Davidson Upgrades Prestige Consumer Healthcare to Buy From Neutral, Adjusts Price Target to $93 From $65	MT
05-15	Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	MT

Prestige Consumer Healthcare Inc. Appoints Dawn M. Zier as Board of Director

May 07, 2020 at 06:16 am

Prestige Consumer Healthcare Inc. announced that Dawn M. Zier, former President and CEO of Nutrisystem was elected to the company’s Board of Directors on May 4, 2020.

Latest news about Prestige Consumer Healthcare Inc.

DA Davidson Upgrades Prestige Consumer Healthcare to Buy From Neutral, Adjusts Price Target to $93 From $65	06-21	MT
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	05-15	MT
Transcript : Prestige Consumer Healthcare Inc., Q4 2024 Earnings Call, May 15, 2024	05-15
North American Morning Briefing : Traders Brace for CPI Inflation Data	05-15	DJ
Prestige Consumer Healthcare Shares Fall Pre-Bell After Fiscal Q4 Miss	05-15	MT
Prestige Consumer Healthcare Fiscal Q4 Adjusted Earnings, Revenue Drop; Fiscal 2025 Outlook Set; Shares Fall After Hours	05-14	MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q4 Revenue $277M, vs. Street Est of $287.4M	05-14	MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Posts Q4 EPS $1.02, vs. Street Est of $1.14	05-14	MT
Prestige Consumer Healthcare Inc. announces an Equity Buyback for $300 million worth of its shares.	05-14	CI
Prestige Consumer Healthcare Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-14	CI
Prestige Consumer Healthcare Inc. Provides Earnings Guidance for the Fiscal Year 2025	05-14	CI
Prestige Consumer Healthcare Inc. authorizes a Buyback Plan.	05-13	CI
Prestige Consumer Healthcare Inc. Appoints John F. Kelly to Board of Directors	05-08	CI
Prestige Consumer Healthcare Insider Sold Shares Worth $1,766,665, According to a Recent SEC Filing	02-16	MT
Prestige Consumer Healthcare Insider Sold Shares Worth $2,051,874, According to a Recent SEC Filing	02-16	MT
Prestige Consumer Healthcare Insider Sold Shares Worth $368,184, According to a Recent SEC Filing	02-12	MT
Prestige Consumer Healthcare's Fiscal Q3 Earnings, Revenue Increase; Raises 2024 Earnings Guidance; Shares Gain	02-08	MT
Transcript : Prestige Consumer Healthcare Inc., Q3 2024 Earnings Call, Feb 08, 2024	02-08
North American Morning Briefing : S&P 500 to Open -2-	02-08	DJ
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q3 Revenue $282.7M, vs. Street Est of $280.4M	02-08	MT
Earnings Flash (PBH) PRESTIGE CONSUMER HEALTHCARE Reports Q3 EPS $1.06, vs. Street Est of $1.04	02-08	MT
Prestige Consumer Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-08	CI
Prestige Consumer Healthcare Inc. Revises Earnings Guidance for the Year of Fiscal 2024	02-08	CI
Prestige Consumer Healthcare Unit Recalls 2 Lots of Ting Antifungal Spray Liquid on High Levels of Benzene	02-02	MT
Prestige Consumer Healthcare Unit Recalls One Lot of Anesthetic Spray Due to Benzene Presence	12-22	MT

Chart Prestige Consumer Healthcare Inc.

Duration

Period

More charts

Prestige Consumer Healthcare Inc. is consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club and e-commerce stores in North America (the United States and Canada) and in Australia and certain other international markets. It operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summerâs Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreauxâs Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q1 2025 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Prestige Consumer Healthcare Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

67.32 USD

Average target price

78.17 USD

Spread / Average Target

+16.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PRESTIGE CONSUMER HEALTHCARE INC.	+10.85%	3.36B
ELI LILLY AND COMPANY	+56.98%	809B
NOVO NORDISK A/S	+39.52%	624B
JOHNSON & JOHNSON	-6.90%	351B
ABBVIE INC.	+7.45%	289B
ASTRAZENECA PLC	+13.74%	240B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.79%	166B
PFIZER, INC.	-2.85%	157B

Other Pharmaceuticals